Funds

Fidelity Advisor® Biotechnology Fund Class A

FBTAX

Fidelity Advisor® Biotechnology Fund Class A

Actions
  • Price (USD)26.57
  • Today's Change-0.22 / -0.82%
  • 1 Year change4.98%
Data delayed at least 15 minutes, as of Jan 27 2020.
More ▼

Asset allocation

Distribution

Type% Net assets% Short% Long
US stock93.49%0.00%93.49%
Non-US stock5.07%0.00%5.07%
Cash0.91%0.00%0.91%
US bond0.00%0.00%0.00%
Non-US bond0.00%0.00%0.00%
Other0.53%0.00%0.53%
As of Nov 30 2019

Weightings

Sectors
Equity
Fixed income
Sector% Net assetsCategory average
Healthcare97.72%97.98%
Other0.00%1.65%
Technology0.00%0.12%
Basic Materials0.00%0.11%
Real Estate0.00%0.06%
Consumer Cyclical0.00%0.05%
Consumer Defensive0.00%0.03%
As of Nov 30 2019. Sectors weighting is calculated using only long position holdings of the portfolio.

Top 10 holdings

Top 10 holdings as a per cent of portfolio
43.85%64.86%0.00%64.86%
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Abbvie Inc
ABBV:NYQ
+8.59%17.94%
Amgen Inc
AMGN:NSQ
+17.13%12.33%
Vertex Pharmaceuticals Inc
VRTX:NSQ
+23.33%10.61%
Alexion Pharmaceuticals Inc
ALXN:NSQ
-10.27%8.14%
Neurocrine Biosciences Inc
NBIX:NSQ
+14.33%3.51%
Alnylam Pharmaceuticals Inc
ALNY:NSQ
+49.65%2.91%
Ascendis Pharma A/S
A71:FRA
+93.75%2.51%
argenx SE ADR--2.34%
FibroGen Inc
FGEN:NSQ
-21.61%2.32%
Gilead Sciences Inc
GILD:NSQ
-5.23%2.25%
Per cent of portfolio in top 10 holdings: 64.86%
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2020
All Rights reserved
© 2020 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.